Skip to Main Content

Paper Details

Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.
Ann Oncol
10
2022
TES, breast cancer, cancer, durvalumab, olaparib, pCR, residual cancer, trial
Author NameAffiliation
Christina YauUniversity of California san francisco
Christina YauUniversity of California san francisco
Rita NandaUniversity of Chicago
Laura J Van't VeerUniversity of California san francisco
William F SymmansThe University of Texas MD Anderson Cancer Center
Lajos PusztaiYale School of Medicine
  • 1 - 6

Datasets

Release 1.2